HC Wainwright Predicts Weaker Earnings for Delcath Systems

Key Points

• HC Wainwright has decreased its FY2026 earnings estimate for Delcath Systems from $0.70 to $0.67 per share, while maintaining a "Buy" rating and a target price of $30.00.
• The consensus estimate for Delcath Systems' current full-year earnings stands at ($0.79) per share, indicating ongoing financial challenges for the company.
• Institutional investors hold 61.12% of Delcath Systems' stock, reflecting significant interest from major financial players in the market.

Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) - Equities research analysts at HC Wainwright dropped their FY2026 earnings estimates for shares of Delcath Systems in a report issued on Monday, October 20th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $0.67 for the year, down from their prior estimate of $0.70. HC Wainwright currently has a "Buy" rating and a $30.00 target price on the stock. The consensus estimate for Delcath Systems' current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Delcath Systems' Q4 2026 earnings at $0.25 EPS and FY2028 earnings at $2.03 EPS.

A number of other research firms have also commented on DCTH. Wall Street Zen lowered Delcath Systems from a "buy" rating to a "hold" rating in a research report on Sunday, October 12th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Delcath Systems in a research report on Wednesday, October 8th. Finally, Stephens restated an "overweight" rating and issued a $25.00 price objective on shares of Delcath Systems in a research report on Monday, June 23rd. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Delcath Systems has a consensus rating of "Moderate Buy" and a consensus price target of $25.33.

Delcath Systems Stock Performance

DCTH opened at $11.42 on Tuesday. The firm has a market cap of $399.47 million, a price-to-earnings ratio of 228.40 and a beta of 0.84. The firm's 50-day simple moving average is $11.04 and its 200-day simple moving average is $12.41. Delcath Systems has a twelve month low of $8.87 and a twelve month high of $18.23.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.05. The company had revenue of $24.16 million for the quarter, compared to analyst estimates of $22.84 million. Delcath Systems had a return on equity of 6.91% and a net margin of 3.18%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Rosalind Advisors Inc. raised its stake in shares of Delcath Systems by 13.8% during the second quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company's stock worth $44,885,000 after buying an additional 400,000 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Delcath Systems by 13.8% in the 1st quarter. Vanguard Group Inc. now owns 1,394,028 shares of the company's stock worth $17,746,000 after purchasing an additional 169,260 shares during the last quarter. Geode Capital Management LLC increased its holdings in Delcath Systems by 128.1% in the second quarter. Geode Capital Management LLC now owns 703,171 shares of the company's stock valued at $9,565,000 after purchasing an additional 394,902 shares during the last quarter. Marshall Wace LLP bought a new stake in Delcath Systems in the second quarter valued at about $6,572,000. Finally, Millennium Management LLC boosted its holdings in Delcath Systems by 34.1% during the first quarter. Millennium Management LLC now owns 422,066 shares of the company's stock worth $5,373,000 after buying an additional 107,391 shares during the last quarter. Institutional investors own 61.12% of the company's stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.